Literature DB >> 6541579

[Hemangioblastomas of the central nervous system. A clinical study].

A Müller-Jensen, W H Zangemeister, J Küchler, H D Herrmann.   

Abstract

In a survey of 46 patients with haemagioblastoma of the CNS (Neurology Dept. University Hamburg, 1950-1980) most (n = 40) were found to have angioblastomas of the cerebellum (Lindau tumors). Of these patients 21 were re-examined in 1983. Headache was the most frequent initial symptom (43%), and within this group one-third (10%-15%) had dizziness, sensorymotor deficits and cerebellar gait disturbances. Signs of elevated intracranial pressure much more often led to the correct diagnosis than dizziness or dystaxia. After the introduction of CCT to the diagnostic procedure the combined evaluation of angiography of the vertebral arteries and CCT always permitted the correct diagnosis. The low neurosurgical mortality rate (13.5%) has decreased to 0% within the last decade. No relapses were found in 21 re-examinations including CCT and EOG compared to a frequency of 9.7% in all 46 cases. Significantly less often than expected from other data we found: signs of possible hereditary influence (0%), multiple tumor localization combined with angiomatosis retinae (0%), polyglobulia (10.8%). Psychopathologically relevant signs (45.6%) were, in all cases, combined with signs of increased intracranial pressure. The results of our re-examination demonstrate that late postoperative deficits as well as possible relapses are earlier and more precisely evaluated by the combined use of clinical examination, CCT and EOG.

Entities:  

Mesh:

Year:  1984        PMID: 6541579     DOI: 10.1007/bf00461553

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  17 in total

1.  The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor.

Authors:  T A WALDMANN; E H LEVIN; M BALDWIN
Journal:  Am J Med       Date:  1961-08       Impact factor: 4.965

2.  The histogenesis of hemangioblastoma of the brain. A review of twenty-one cases.

Authors:  A A STEIN; A O SCHILP; R D WHITFIELD
Journal:  J Neurosurg       Date:  1960-07       Impact factor: 5.115

3.  Cerebellar hemangioma (hemangioblastoma); a clinicopathological review of 40 cases.

Authors:  M L SILVER; G HENNIGAR
Journal:  J Neurosurg       Date:  1952-09       Impact factor: 5.115

4.  Haemangioblastomas. A review of 81 cases.

Authors:  J J Palmer
Journal:  Acta Neurochir (Wien)       Date:  1972       Impact factor: 2.216

5.  [Recurrences in Lindau's tumors. Observations on 57 cases of hemangioblastomas of the cerebellum].

Authors:  J Lizuka
Journal:  Acta Neurochir (Wien)       Date:  1969       Impact factor: 2.216

6.  Cerebellar haemangioblastomas.

Authors:  V P Mondkar; W McKissock; R W Russell
Journal:  Br J Surg       Date:  1967-01       Impact factor: 6.939

7.  CT scanning for the diagnosis of the cerebrellar and spinal lesions of von Hippel-Lindau's disease.

Authors:  D Balériaux-Waha; J Retif; J Noterman; G Terwinghe; L L Mortelmans; M G Dupont; L Jeanmart
Journal:  Neuroradiology       Date:  1978-02-17       Impact factor: 2.804

8.  Pathological and haematological aspects of posterior fossa haemangioblastomata.

Authors:  R Jeffreys
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-02       Impact factor: 10.154

9.  The complementary nature of computed tomography and angiography in the diagnosis of cerebellar hemangioblastoma.

Authors:  S H Cornell; N S Hibri; A H Menezes; C J Graf
Journal:  Neuroradiology       Date:  1979-04-26       Impact factor: 2.804

10.  Vestibulo-oculomotor characteristics in surgically treated patients with cerebellar haemangioblastoma (Lindau tumor).

Authors:  W H Zangemeister; A Mueller-Jensen
Journal:  Acta Otolaryngol Suppl       Date:  1984
View more
  1 in total

1.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.